NeuroMax obtains global rights for new neuropathic pain reliever
NeuroMax, a Russian biotech company, has obtained from U.S.-based Aquilus Pharmaceuticals the global rights to develop and market the NM-AQU-005, a neuropathic pain treatment drug.
NeuroMax, a Russian biotech company, announced earlier this summer that it has inked a license agreement with U.S.-based Aquilus Pharmaceuticals, Inc. which grants Neuromax the global rights to develop and market the NM-AQU-005, an innovative drug to treat neuropathic pain. The new drug candidate is a low-molecule inhibitor of matrix metalloproteinases (MMPs) designed to treat neuropathic pain caused by a variety of disorders, including diabetic neuropathy. According to the developers, selective inhibition of two most developed targets (MMP-2 and MMP-9) is expected to help prevent the development of neuropathic pain, a result of degenerative processes in the nerve cells. The candidate?s perceived dual mechanism of action gives ground to expect a long-lasting therapeutic effect, the developers say...
NeuroMax, a Russian biotech company, announced earlier this summer that it has inked a license agreement with U.S.-based Aquilus Pharmaceuticals, Inc. which grants Neuromax the global rights to develop and market the NM-AQU-005, an innovative drug to treat neuropathic pain. The new drug candidate is a low-molecule inhibitor of matrix metalloproteinases (MMPs) designed to treat neuropathic pain caused by a variety of disorders, including diabetic neuropathy. According to the developers, selective inhibition of two most developed targets (MMP-2 and MMP-9) is expected to help prevent the development of neuropathic pain, a result of degenerative processes in the nerve cells. The candidate?s perceived dual mechanism of action gives ground to expect a long-lasting therapeutic effect, the developers say...
Похожее
NeuroMax steps up testing of its drug for diabetes complications
Russian developer pushes brand new tuberculosis drug
Yaroslavl biotech innovators develop new chronic C-type hepatitis drug
Russian biotech company obtains US patent for brand new cancer drug
Rusnano asset launches UK sales of new osteoarthritis pain reliever
New C-type hepatitis drug safe, no side effect, developer claims